1-3 of 3
Lori Hazlehurst, PhD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Phase I Study of Ruxolitinib Plus Nilotinib in Chronic Phase CML Patients with Molecular Evidence of Disease

Kendra L. Sweet, MD, Lori Hazlehurst, PhD, Eva Sahakian, PhD, John J. Powers, B.S., Lisa Nodzon, PhD ANP, Fadi Kayali, MD, Kelly Hyland, Ashley Nelson, Javier Pinilla-Ibarz, MD PhD
Journal: Blood
Blood (2016) 128 (22): 1892.
https://doi.org/10.1182/blood.V128.22.1892.1892
Published: 2016
Journal Articles

Targeting PYK2 Mediates Microenvironment-Specific Myeloma Cell Death

Kenneth H. Shain, MD PhD, Mark B Meads, PhD, Bin Fang, PhD, Linda Mathews, Jennifer Gemmer, Liang Nong, MD, Ismael Rosado-Lopez, BS, Jennifer E. Ring, Robert MacLeod, PhD, Lori Hazlehurst, PhD, Conor Lynch, PhD, Jonathan A. Pachter, PhD, William Matsui, MD, John Koomen, PhD, Tuan Nguyen
Journal: Blood
Blood (2014) 124 (21): 2081.
https://doi.org/10.1182/blood.V124.21.2081.2081
Published: 2014
Journal Articles

Influence of Targeted Therapy in Redefining High-Risk Myeloma.

Lori Hazlehurst, PhD, William S. Dalton, MD, PhD, Danielle Yarde, Yulia Nefedova, MD, PhD, Dmitry Gabrilovich
Journal: Blood
Blood (2008) 112 (11): sci-7.
https://doi.org/10.1182/blood.V112.11.sci-7.sci-7
Published: 2008